Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong ...

Eli Lilly and Novo Nordisk didn't quite beat expectations with their recent earnings. Their weight loss drugs slightly underperformed. That underperformance may portend more difficulty.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low volatility stocks. We will also discuss the latest updates around the market and ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to buy according to Billionaire Ken Fisher. Ken Fisher is a prominent ...

Eli Lilly's weight loss drug sales in Q3 weren't as strong as it anticipated. Its earnings will continue to grow at a rapid pace regardless. It still has a couple of levers it can pull to drive ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings ...

If you looked solely at its stock price, you might get the idea that Eli Lilly (NYSE: LLY) is having a bit of an off quarter. Over the past 30 days, its shares fell by about 10%, though they are ...